Developer docs
API playgroundTry for free, no card

Search company profiles

Eyconis

Full company profile

uuid0002ah9

Namestring
Eyconis
Legal namestring
Eyconis, Inc.
Websiteurl
eyconis.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Eyconis is a privately held, pre-clinical stage biopharmaceutical company founded in 2023 as a spinout of Ascendis Pharma (NASDAQ: ASND) and headquartered at 1200 Bridge Parkway, Suite 200, Redwood City, California. The company holds an exclusive, worldwide license to Ascendis's TransCon technology platform for ophthalmology applications, and is using that platform to develop long-acting therapeutics for the major causes of blindness, with an initial lead candidate targeting wet age-related macular degeneration (AMD) and additional programs directed at diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA).

The core technology — TransCon — combines known biology with prodrug and sustained-release technologies to produce a desired pharmacokinetic profile with predictable release of unmodified parent drug, supporting dosing intervals of six months or more. By localizing TransCon to ophthalmology, Eyconis is positioning to deliver clinically validated anti-VEGF and emerging medicines at substantially reduced injection frequency compared with the current standard of care (e.g., EYLEA, Lucentis, Vabysmo), which it intends to improve upon rather than displace at the molecular level.

Eyconis is pre-commercial and generates no product revenue today; future revenue, upon regulatory approval, is expected to come from sale of approved ophthalmology pharmaceuticals through traditional specialty pharmacy and physician-channel distribution. The company launched in 2023 with a $150 million external investor commitment from Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital, with Ascendis Pharma retaining equity and milestone ("biobucks") participation. In February 2024 Eyconis closed an additional ~$60.25 million tranche, and in October 2025 it filed a Form D exempt offering valued at approximately $89.75 million (~ $25 million already sold), reflecting continued capital deployment into IND-enabling activities and pipeline expansion. The senior leadership includes veterans of the EYLEA/EYLEA HD program at Regeneron (Vitti, Chu, Drosman) and the Lucentis/Vabysmo programs at Genentech/Roche (Stauch), signaling a deliberate capability bet on long-acting delivery within established anti-VEGF biology.

Short descriptiontext

Eyconis is a pre-clinical stage biopharmaceutical company developing long-acting ophthalmology therapeutics using the TransCon prodrug/sustained-release technology platform licensed exclusively from Ascendis Pharma, targeting wet AMD, DME, RVO, and geographic atrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmology therapeutics, retinal disease treatments, sustained-release drug delivery, ophthalmic biopharmaceuticals, TransCon prodrug platform
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-commercial stage company. Eyconis is developing novel therapeutics for eye diseases (wet AMD, DME, RVO, GA) using TransCon technology. Revenue will be generated through sale of approved pharmaceutical products for ophthalmology upon successful clinical development and regulatory approval.

eyconis.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, long-acting ophthalmology therapeutics based on the TransCon technology platform licensed exclusively worldwide from Ascendis Pharma. Its lead drug candidate targets wet age-related macular degeneration (AMD), with additional preclinical programs for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA), all designed to achieve dosing intervals of six months or more.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, best-in-class therapeutics for eye diseases using the TransCon technology platform licensed exclusively from Ascendis Pharma. The company's lead drug candidate targets wet age-related macular degeneration (AMD), with additional programs in development for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). The TransCon platform enables long-acting delivery of clinically validated and emerging medicines, potentially achieving six-month dosing intervals.

Product and service2 records
1TransCon Technology Platform for Ophthalmology
CategoryDrug delivery technology platform
Description

A clinically validated drug development platform combining known biology with prodrug and sustained-release technologies to enable long-acting delivery of ophthalmology therapeutics, supporting dosing frequency of six months or more. Licensed exclusively worldwide from Ascendis Pharma for ophthalmology applications and used by Eyconis to develop its pipeline of treatments for major causes of blindness.

2Lead TransCon Ophthalmology Drug Candidate (Wet AMD Program)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Ascendis Pharma granted Eyconis exclusive, worldwide license to develop, manufacture, and commercialize ophthalmology therapeutics using its clinically validated TransCon technology platform. Eyconis is a spinout of Ascendis Pharma, founded in 2023. Ascendis CEO Jan Møller Mikkelsen serves on Eyconis' Board of Directors.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

REGENXBIO is developing RGX-314 (in collaboration with AbbVie) for wet AMD and diabetic retinopathy using subretinal/suprachoroidal AAV gene therapy to provide sustained anti-VEGF expression. It is a key emerging competitor in long-acting wet AMD delivery.

TypeDirect peer
Description

Kodiak Sciences is a clinical-stage ophthalmology biotech developing long-acting retinal therapies (tarcocimab and next-generation antibodies) targeting wet AMD, DME, and RVO. It is one of the closest publicly traded comparables in long-acting retinal biologics.

TypeEmerging player
Description

Outlook Therapeutics is a pre-commercial ophthalmology company developing ONS-5010/LYTENAVA (bevacizumab-vikg), an ophthalmic formulation for wet AMD. It is a comparable pre-revenue ophthalmology biotech pursuing retina indications.

TypeEmerging player
Description

4DMT is a clinical-stage genetic medicines company developing 4D-150 for wet AMD using intravitreal AAV gene therapy. It is an emerging long-acting delivery competitor in the same retinal indication space.

TypeEmerging player
Description

Clearside Biomedical develops suprachoroidal delivery technology for retinal therapeutics (XIPERE approved for macular edema associated with uveitis). Its suprachoroidal platform is a comparable long-acting ocular delivery approach addressing similar retina specialist customers.

TypeDirect peer
Description

Adverum is a clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD, positioning long-duration delivery against frequent anti-VEGF injections. It is a directly comparable emerging modality in the same retinal indications.

TypeBroad incumbent
Description

Apellis markets SYFOVRE (pegcetacoplan) for geographic atrophy, one of Eyconis's named target indications. As a recently launched ophthalmology biotech with an approved complement-based retinal drug, Apellis is a relevant late-stage comparator in GA.

TypeEmerging player
Description

Annexon is a clinical-stage biotech developing tanruprubart for geographic atrophy, targeting complement C1q to address GA. It is an emerging player with meaningful overlap in Eyconis's GA program target indication.

TypeBroad incumbent
Description

Regeneron markets EYLEA and EYLEA HD, the dominant anti-VEGF therapies for wet AMD, DME, and RVO that Eyconis aims to disrupt. Several Eyconis executives (Vitti, Chu, Drosman) led EYLEA development at Regeneron, making it the most relevant incumbent comparator in retinal disease.

TypeBroad incumbent
Description

Roche/Genentech markets Vabysmo (faricimab) and Lucentis, the principal dual-pathway/biologic competitors in wet AMD and DME. Eyconis COO Oliver Stauch led Lucentis and Vabysmo delivery innovation at Roche, making this the second key incumbent benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eyconis

Ophthalmic Pharmaceuticalseyconis.com

Eyconis is a pre-clinical stage biopharmaceutical company developing long-acting ophthalmology therapeutics using the TransCon prodrug/sustained-release technology platform licensed exclusively from Ascendis Pharma, targeting wet AMD, DME, RVO, and geographic atrophy.

What Eyconis does

Eyconis is a privately held, pre-clinical stage biopharmaceutical company founded in 2023 as a spinout of Ascendis Pharma (NASDAQ: ASND) and headquartered at 1200 Bridge Parkway, Suite 200, Redwood City, California. The company holds an exclusive, worldwide license to Ascendis's TransCon technology platform for ophthalmology applications, and is using that platform to develop long-acting therapeutics for the major causes of blindness, with an initial lead candidate targeting wet age-related macular degeneration (AMD) and additional programs directed at diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA).

The core technology — TransCon — combines known biology with prodrug and sustained-release technologies to produce a desired pharmacokinetic profile with predictable release of unmodified parent drug, supporting dosing intervals of six months or more. By localizing TransCon to ophthalmology, Eyconis is positioning to deliver clinically validated anti-VEGF and emerging medicines at substantially reduced injection frequency compared with the current standard of care (e.g., EYLEA, Lucentis, Vabysmo), which it intends to improve upon rather than displace at the molecular level.

Eyconis is pre-commercial and generates no product revenue today; future revenue, upon regulatory approval, is expected to come from sale of approved ophthalmology pharmaceuticals through traditional specialty pharmacy and physician-channel distribution. The company launched in 2023 with a $150 million external investor commitment from Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital, with Ascendis Pharma retaining equity and milestone ("biobucks") participation. In February 2024 Eyconis closed an additional ~$60.25 million tranche, and in October 2025 it filed a Form D exempt offering valued at approximately $89.75 million (~ $25 million already sold), reflecting continued capital deployment into IND-enabling activities and pipeline expansion. The senior leadership includes veterans of the EYLEA/EYLEA HD program at Regeneron (Vitti, Chu, Drosman) and the Lucentis/Vabysmo programs at Genentech/Roche (Stauch), signaling a deliberate capability bet on long-acting delivery within established anti-VEGF biology.

Eyconis firmographics

Firmographics
Name
Eyconis
Legal name
Eyconis, Inc.
Website
https://eyconis.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Eyconis is a pre-clinical stage biopharmaceutical company developing long-acting ophthalmology therapeutics using the TransCon prodrug/sustained-release technology platform licensed exclusively from Ascendis Pharma, targeting wet AMD, DME, RVO, and geographic atrophy.
Ownership category
akta.pro rank

Eyconis industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmology therapeutics
  • Retinal disease treatments
  • Sustained-release drug delivery
  • Ophthalmic biopharmaceuticals
  • TransCon prodrug platform

Where Eyconis is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Eyconis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Revenue: Pre-commercial stage company. Eyconis is developing novel therapeutics for eye diseases (wet AMD, DME, RVO, GA) using TransCon technology. Revenue will be generated through sale of approved pharmaceutical products for ophthalmology upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels3 records

Eyconis product offering

Product offering

Core offering

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, long-acting ophthalmology therapeutics based on the TransCon technology platform licensed exclusively worldwide from Ascendis Pharma. Its lead drug candidate targets wet age-related macular degeneration (AMD), with additional preclinical programs for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA), all designed to achieve dosing intervals of six months or more.

Product overview

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, best-in-class therapeutics for eye diseases using the TransCon technology platform licensed exclusively from Ascendis Pharma. The company's lead drug candidate targets wet age-related macular degeneration (AMD), with additional programs in development for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). The TransCon platform enables long-acting delivery of clinically validated and emerging medicines, potentially achieving six-month dosing intervals.

Differentiator

Problem solved

Functional benefit

Products and services

  • TransCon Technology Platform for Ophthalmology A clinically validated drug development platform combining known biology with prodrug and sustained-release technologies to enable long-acting delivery of ophthalmology therapeutics, supporting dosing frequency of six months or more. Licensed exclusively worldwide from Ascendis Pharma for ophthalmology applications and used by Eyconis to develop its pipeline of treatments for major causes of blindness.
  • Lead TransCon Ophthalmology Drug Candidate (Wet AMD Program)

Companies that use Eyconis

Customer profile

Segments2 records

Ideal customer profiles2 records

Eyconis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Eyconis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ascendis Pharma A/ScoreStrategic or Co-development Partner · 1 January 2023Ascendis Pharma granted Eyconis exclusive, worldwide license to develop, manufacture, and commercialize ophthalmology therapeutics using its clinically validated TransCon technology platform. Eyconis is a spinout of Ascendis Pharma, founded in 2023. Ascendis CEO Jan Møller Mikkelsen serves on Eyconis' Board of Directors.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Eyconis competitors and assessment

Company assessment

Direct peers

  • REGENXBIO: REGENXBIO is developing RGX-314 (in collaboration with AbbVie) for wet AMD and diabetic retinopathy using subretinal/suprachoroidal AAV gene therapy to provide sustained anti-VEGF expression. It is a key emerging competitor in long-acting wet AMD delivery.
  • Kodiak Sciences: Kodiak Sciences is a clinical-stage ophthalmology biotech developing long-acting retinal therapies (tarcocimab and next-generation antibodies) targeting wet AMD, DME, and RVO. It is one of the closest publicly traded comparables in long-acting retinal biologics.
  • Adverum Biotechnologies: Adverum is a clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD, positioning long-duration delivery against frequent anti-VEGF injections. It is a directly comparable emerging modality in the same retinal indications.

Emerging players

  • Outlook Therapeutics: Outlook Therapeutics is a pre-commercial ophthalmology company developing ONS-5010/LYTENAVA (bevacizumab-vikg), an ophthalmic formulation for wet AMD. It is a comparable pre-revenue ophthalmology biotech pursuing retina indications.
  • 4D Molecular Therapeutics: 4DMT is a clinical-stage genetic medicines company developing 4D-150 for wet AMD using intravitreal AAV gene therapy. It is an emerging long-acting delivery competitor in the same retinal indication space.
  • Clearside Biomedical: Clearside Biomedical develops suprachoroidal delivery technology for retinal therapeutics (XIPERE approved for macular edema associated with uveitis). Its suprachoroidal platform is a comparable long-acting ocular delivery approach addressing similar retina specialist customers.
  • Annexon, Inc. Annexon is a clinical-stage biotech developing tanruprubart for geographic atrophy, targeting complement C1q to address GA. It is an emerging player with meaningful overlap in Eyconis's GA program target indication.

Broad incumbents

  • Apellis Pharmaceuticals: Apellis markets SYFOVRE (pegcetacoplan) for geographic atrophy, one of Eyconis's named target indications. As a recently launched ophthalmology biotech with an approved complement-based retinal drug, Apellis is a relevant late-stage comparator in GA.
  • Regeneron Pharmaceuticals: Regeneron markets EYLEA and EYLEA HD, the dominant anti-VEGF therapies for wet AMD, DME, and RVO that Eyconis aims to disrupt. Several Eyconis executives (Vitti, Chu, Drosman) led EYLEA development at Regeneron, making it the most relevant incumbent comparator in retinal disease.
  • Roche/Genentech: Roche/Genentech markets Vabysmo (faricimab) and Lucentis, the principal dual-pathway/biologic competitors in wet AMD and DME. Eyconis COO Oliver Stauch led Lucentis and Vabysmo delivery innovation at Roche, making this the second key incumbent benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Eyconis social profiles

Digital presence

Eyconis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eyconis leadership team

Management profile

Number of profiles

Profiles12 records

Eyconis funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eyconis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyconis

What does Eyconis do?

Eyconis is a pre-clinical stage biopharmaceutical company developing a pipeline of novel, long-acting ophthalmology therapeutics based on the TransCon technology platform licensed exclusively worldwide from Ascendis Pharma. Its lead drug candidate targets wet age-related macular degeneration (AMD), with additional preclinical programs for diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA), all designed to achieve dosing intervals of six months or more.

Is Eyconis a public or private company?

Eyconis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eyconis founded?

Eyconis was founded in 2023. It employs 11 to 50 people.

Where is Eyconis based?

Eyconis is headquartered in Redwood City, United States, in the North America region.

How does Eyconis make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Eyconis's main competitors?

Direct peers on record are REGENXBIO, Kodiak Sciences and Adverum Biotechnologies. Emerging players are Outlook Therapeutics, 4D Molecular Therapeutics, Clearside Biomedical and Annexon, Inc.. Broad incumbents are Apellis Pharmaceuticals, Regeneron Pharmaceuticals and Roche/Genentech.

Does Eyconis have an API?

No public API is recorded for Eyconis.

What industry is Eyconis in?

Eyconis's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialEyconis To Participate In Upcoming Investor ConferencesEyconis will participate in six investor conferences from November to December 2026, including virtual and in-person events. The company's lead program, EYC-0305, is a long-acting anti-VEGF therapy for wet age-related macular degeneration, currently in a Phase 1b/2a trial.BioSpaceEyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration PatientsEyconis initiated OVERTURE, its first-in-human Phase 1b/2a trial of EYC-0305 in treatment-naïve wet AMD patients, with first patients dosed. The study evaluates safety, tolerability, and pharmacokinetics, aiming for six-month or longer dosing intervals. The company expects to inform next-stage development, including durability beyond six months.SecSEC FORM DEyconis, Inc. filed a Form D notice with the SEC on October 22, 2025, notifying regulators of an exempt offering of equity securities under Rule 506(b). The company, incorporated in Delaware in 2023, is seeking to raise approximately $89.75 million, with $25 million already sold to 7 investors as of the first sale date on October 8, 2025. The offering is structured as equity with no minimum investment requirement and no sales commissions or finder's fees.GlobeNewswireEyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of DirectorsEyconis, Inc. appointed Dr. Mark J. Bachleda as CEO and board member. He previously served as Chief Commercial Officer at Galera Therapeutics and held roles at Amgen, Juno, and BMS. The company is advancing its pipeline for age-related macular degeneration.SecSEC FORM DEyconis, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with a total offering amount of $150,001,250. The company has sold $60,251,247 worth of securities to seven investors since the first sale on January 26, 2024. This regulatory filing discloses the ongoing capital raise by the Delaware-based biotechnology firm.pharmaphorumVera prices $250m offer, and other biotech financingsVera Therapeutics priced a $250 million public offering of common stock at $31 per share, following positive clinical data for its IgA nephropathy drug ataticept. In related biotech financing news, CAR-T specialist Kyverna filed for an IPO to raise approximately $211 million, while several other companies including Eyconis and COUR Pharmaceuticals secured significant private funding rounds.